{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:27Z","timestamp":1791489627533,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":271,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101462","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:11:06Z","timestamp":1791367866000},"page":"101462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Ruihe","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101462_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101462_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2024.02.006","article-title":"Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: a large-scale, multicenter, real-world study (NeoR-World)","volume":"168","author":"Yang","year":"2024","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101462_bib0003","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.21.01589","article-title":"Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer","volume":"40","author":"Chaft","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101462_bib0004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.athoracsur.2023.06.004","article-title":"Recurrence after complete resection for non-small cell lung cancer in the national lung screening trial","volume":"116","author":"Potter","year":"2023","journal-title":"Ann. Thorac. Surg."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101462_bib0005","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101462_bib0006","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101462_bib0007","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jtho.2018.09.017","article-title":"Current status and future perspectives on neoadjuvant therapy in lung cancer","volume":"13","author":"Blumenthal","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101462_bib0008","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtho.2024.09.022","article-title":"OA01.03 Association of Pathologic regression with EFS in the KEYNOTE-671 study of perioperative Pembrolizumab for early-stage NSCLC","volume":"19","author":"Jones","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101462_bib0009","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101462_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2026.02.025","article-title":"Pathological response and nodal status guide Adjuvant immunotherapy in NSCLC after neoadjuvant chemoimmunotherapy: an eastern Asian cohort study","volume":"172","author":"Pan","year":"2026","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101462_bib0011","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.21037\/jtd-2024-2200","article-title":"Prognosis and relapse patterns in patients with non-small cell lung cancer with pathologic complete response after neoadjuvant immunochemotherapy","volume":"17","author":"Fang","year":"2025","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101462_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2024.11.028","article-title":"Adjuvant immunotherapy does not improve survival in non-small cell lung cancer with major\/complete pathologic response after induction immunotherapy","volume":"169","author":"Zhao","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101462_bib0013","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/his.14855","article-title":"Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy","volume":"82","author":"Xia","year":"2023","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101462_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101462_bib0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101462_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110425","article-title":"Classification of recurrence patterns in surgically treated non-small cell lung cancer - A systematic review and a call for standardization","volume":"51","author":"Bonis","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101462_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2025.04.028","article-title":"Lung cancer recurrence after neoadjuvant immunotherapy","volume":"170","author":"Li","year":"2025","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101462_bib0018","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101462_bib0019","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101462_bib0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10555-022-10075-x","article-title":"Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors","volume":"42","author":"Heidrich","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ctarc.2026.101462_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114212","article-title":"An aminopeptidase N-activatable chemiluminescence probe for image-guided surgery and metastasis tracking of tumor","volume":"208","author":"Shi","year":"2022","journal-title":"Biosens. Bioelectron."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101462_bib0022","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s13402-025-01067-4","article-title":"Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer","volume":"48","author":"Zhao","year":"2025","journal-title":"Cell Oncol. (Dordr.)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101462_bib0023","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-025-02435-0","article-title":"CD8(+) TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients","volume":"10","author":"Lin","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101462_bib0024","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41591-024-03240-y","article-title":"Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab","volume":"30","author":"Alban","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101462_bib0025","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO-25-00610","article-title":"Phase III study of mediastinal lymph node dissection for ground glass opacity-dominant lung adenocarcinoma","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101462_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101462_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:41:05Z","timestamp":1791488465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":27,"alternative-id":["S2468294226003722"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101462","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101462"}}